Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE

被引：0

作者：

Reiser, M. ^{[1
]}

Uhlig, J. ^{[2
]}

Jacobasch, L. ^{[3
]}

Mueller, L. ^{[4
]}

Schuch, A. ^{[5
]}

Serrer, L. ^{[5
]}

de Buhr, R. ^{[6
]}

Siebenbach, H. U. ^{[7
]}

Goehler, T. ^{[8
]}

Schroeder, K. ^{[9
]}

Semsek, D. ^{[10
]}

Koehler, A. ^{[11
]}

Stuebs, P. ^{[12
]}

Potthoff, K. M. ^{[6
]}

Marschner, N. W. ^{[6
]}

机构：

[1] Praxis Internist Onkol & Hamatol, PIOH Koln Zentrum, Cologne, Germany

[2] Praxis Dr Med Jens Uhlig, Naunhof, Germany

[3] Gemeinschaftspraxis Haematol Onkol, Oncol Heamatol Dept, Dresden, Germany

[4] Onkol Untere Ems Leer Papenburg Emden, Leer, Germany

[5] IOMEDICO AG, Clin Operat, Freiburg, Germany

[6] IOMEDICO AG, Med Dept, Freiburg, Germany

[7] IOMEDICO AG, Biostat, Freiburg, Germany

[8] Onkol Gemeinschaftspraxis, Dresden, Germany

[9] MVZ Hamatol & Onkol Mulheim Ruhr, Mulheim, Germany

[10] Praxis Interdisziplinaere Onkol & Haematol, Freiburg, Germany

[11] Onkol Schwerpunktpraxis, Langen, Hessen, Germany

[12] DRK Kliniken Berlin Kopenick, Klinik Allgemein Viszeral & Minimalinvas Chirurg, Berlin, Germany

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1813

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

622P

引用

页码：S445 / S445

页数：1

共 50 条

[1] Prospective validation of the metastatic colon cancer score (mCCS) in patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE
Marschner, N. W.
Uhlig, J.
Jacobasch, L.
Mueller, L.
Reiser, M.
Schuch, A.
Serrer, L.
de Buhr, R.
Siebenbach, H. U.
Goehler, T.
Schroeder, J. K.
Semsek, D.
Koehler, A.
Stuebs, P.
Potthoff, K. M.
ANNALS OF ONCOLOGY, 2024, 35 : S473 - S473
[2] 1st-line panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany: Interim results of the non-interventional study VALIDATE
Uhlig, J.
Potenberg, J.
Semsek, D.
Stuebs, P.
Fichter, C. D.
Koehler, A.
Mueller, L.
Reiser, M.
Siebenbach, H. U.
Goehler, T.
Jacobasch, L.
Kaechele, V.
Timm, B.
Potthoff, K.
Marschner, N. W.
ANNALS OF ONCOLOGY, 2020, 31 : S436 - S436
[3] Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI - Interim results of the non-interventional study QoLiTrap
Scholten, F.
Derigs, G.
Losem, C.
Kroening, H.
Windemuth-Kieselbach, C.
Hofheinz, R. D.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 163 - 163
[4] Impact of tumour RAS/BRAF status in a first-line study of panitumumab plus FOLFIRI in patients with metastatic colorectal cancer
Karthaus, Meinolf
Hofheinz, Ralf-Dieter
Mineur, Laurent
Letocha, Henry
Greil, Richard
Thaler, Josef
Fernebro, Eva
Oliner, Kelly S.
Boedigheimer, Michael
Twomey, Brian
Zhang, Ying
Demonty, Gaston
Koehne, Claus-Henning
BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1215 - 1222
[5] Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI: Interim results of the non-interventional AIO study QoLiTrap
Zahn, M.
Scholten, F.
von Moos, R.
Thaler, J.
Hofheinz, R.
ANNALS OF ONCOLOGY, 2018, 29
[6] Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI - Interim results of the non-interventional AIO study QoLiTrap
von Moos, R.
Derigs, G.
Scholten, F.
Thaler, J.
Losem, C.
Kroening, H.
Windemuth-Kieselbach, C.
Hofheinz, R. D.
ANNALS OF ONCOLOGY, 2017, 28
[7] Analysis of the quality of life in patients treated with Aflibercept and FOLFIRI for metastatic colorectal cancer (mCRC) - Interim results from the non-interventional QoLiTrap study
Derigs, H. -G
Scholten, F.
Losem, C.
Kroening, H.
Windemuth-Kieselbach, C.
Hofheinz, R. -D
Oncology Research and Treatment, 2015, 38 : 61 - 62
[8] Sequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first-line (1L): PERSEIDA study
Valladares-Ayerbes, M.
Garcia-Alfonso, P.
Munoz Luengo, J.
Pimentel Caceres, P.
Vieitez, J. M.
Cruz-Hernandez, J. J.
Llanos, M.
Garcia Giron, C.
Cirera, L.
Lloansi Vila, A.
ANNALS OF ONCOLOGY, 2019, 30 : 202 - 202
[9] Final results of the non-interventional study QoLiTrap (AIOLQ-0113) in patients with metastatic colorectal cancer (mCRC) treated with aflibercept plus FOLFIRI
Scholten, F.
von Moos, R.
Derigs, H. -G.
Hofheinz, R. -D.
Thaler, J.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 128 - 128
[10] Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
Meinolf Karthaus
Ralf-Dieter Hofheinz
Laurent Mineur
Henry Letocha
Richard Greil
Josef Thaler
Eva Fernebro
Kelly S Oliner
Michael Boedigheimer
Brian Twomey
Ying Zhang
Gaston Demonty
Claus-Henning Köhne
British Journal of Cancer, 2016, 115 : 1215 - 1222

← 1 2 3 4 5 →